Notice of Results and Investor Presentation

RNS Number : 4182R

Omega Diagnostics Group PLC

05 November 2021

 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

Notice of Results

Investor Presentation

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, announces it will release its interim results for the six months ended 30 September 2021 on Thursday 25 November 2021.

Investor presentation

Colin King, CEO, and Chris Lea, CFO, will provide a live presentation relating to the Interim Results via the Investor Meet Company platform on 25 November 2021 at 4:30pm GMT.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet OMEGA DIAGNOSTICS GROUP PLC via:

https://www.investormeetcompany.com/omega-diagnostics-group-plc/register-investor  

Investors who already follow OMEGA DIAGNOSTICS GROUP PLC on the Investor Meet Company platform will automatically be invited.

Contacts: 

Omega Diagnostics Group PLC	www.omegadx.com
Colin King, Chief Executive	via Walbrook PR
Chris Lea, Chief Financial Officer
finnCap Ltd	Tel: [phone]
Geoff Nash/Edward Whiley (Corporate Finance)
Alice Lane/ Charlotte Sutcliffe (ECM)
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Applegarth	Mob: [phone]
Sam Allen	Mob: [phone]

About Omega Diagnostics Group PLC

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 75 countries and specialise in the areas of health and nutrition and global health.

www.omegadx.com

 

END

 

 

NORFSLFMLEFSEIF